National Comprehensive Cancer Network
- Educational Events & Programs
- NCCN Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™
- NCCN Annual Congress: Hematologic Malignancies™
- Regional Guidelines in Oncology Symposia
- NCCN Guidelines Update Webinar Series™
- State-of-the-Art Approaches to the Treatment of NSCLC
- NCCN Academy for Excellence & Leadership in Oncology™
- NCCN Resource Tool: REMS
- NCCN CME/CE Programs
- NCCN Oncology Case Management Program™
- NCCN International Programs
Clinical Recommendations
|
|
NCCN 3rd Annual Congress: Hematologic Malignancies – Management of Progressive Disease and Management of TKI ToxicityRecorded at the NCCN 3rd Annual Congress: Hematologic Malignancies held September 5-6, 2008, in New York, New York Presenters Update on Front-Line Therapy of CML with Imatinib and Results with Second-Generation Tyrosine Kinase Inhibitors Combating Progressive Disease by Monitoring and Early Detection: War and PCR Faculty Disclosure Statements Susan O’Brien, MD Dr. O’Brien has disclosed that she has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the educational activity. She has received grant/research support from Berlex Inc.; Biogen Idec; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; and Novartis Pharmaceuticals Corporation. Dr. O’Brien has indicated that her presentation will not include discussion of investigational or unlabeled uses of commercial products. Jerald P. Radich, MD Dr. Radich has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the educational activity. He has received grant/research support from and has served as a consultant and scientific advisor for Bristol-Myers Squibb Company. Dr. Radich has indicated that his presentation will not include discussion of investigational or unlabeled uses of commercial products. Program Goal The goal of this presentation is to educate health care provides about new approaches that have been incorporated into the management of chronic myelogenous leukemia, including the use of drugs, biologics, and diagnostics. Educational Objectives Following this activity, participants should be able to:
Intended Audience This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer. Activity Instructions Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than November 5, 2009. There is no fee for participating in this activity. Accreditation Information Physicians The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians. NCCN designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Nurses This activity is approved for 1.3 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity. Release date: November 5, 2008 Commercial Support Supported by educational grants from Bristol-Myers Squibb Company and Novartis Oncology
|
E-mail
Print
Mark
|
|
|
|
|
|
|
||